Shares of Novavax, Inc. (NVAX) plunged over 19.5% on Thursday after Health and Human Services Secretary Robert F. Kennedy Jr.

Novavax shifts to a partnership-focused strategy with a $500M Sanofi deal. Despite regulatory and competitive risks. See why ...

Shares of vaccine makers fell after US Health and Human Services Secretary Robert F. Kennedy Jr. raised doubts about the ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

Dr. Peter Marks, an ex-FDA vaccine official, is warning of a fundamental change at the agency—where vaccine skepticism now ...

Health secretary Robert F. Kennedy Jr. has expressed another unorthodox view on vaccines, with the long-time vaccine critic declaring that vaccines for respiratory bugs that target a sole part of ...

Peer-reviewed journals rejected their followup study on the 2023-2024 formulation of mRNA vaccines against the JN.1 variant ...

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay.

In today's Morning Rounds newsletter, RFK Jr.'s latest theory about vaccines, how sweeping FDA layoffs could impact drug ...

Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.

The agency is sitting on a decision to grant full approval for Novavax’s shot, days after top vaccine regulator pushed out.

Novavax (NasdaqGS:NVAX) experienced a noteworthy 13% increase in its share price last week, coinciding with significant changes in its leadership. The retirement of James Young as Chair of the Board ...